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After antigen recognition, naive T cells expand 
and differentiate into a large pool of effector   
T cells. Most of the effector T cells die during a 
phase of contraction after antigen is no longer 
available; however, a small proportion survive 
and differentiate into memory T cells that con­
fer protective immunity to the host (Seder and 
Ahmed, 2003; McKinstry et al., 2008). In some 
situations, memory T cells also contribute to 
the  development  of  inflammatory  and  auto­
immune disease (Bradley et al., 2000; Kuchroo   
et  al.,  2002).  The  overall  size  of  the  initial 
memory T cell pool is determined by several 
factors, including the strength of naive T cell 
activation, the extent of primary clonal expan­
sion, and the survival of effector T cells during 
the contraction phase of the primary response. 
Many studies have clearly demonstrated that 
co­stimulatory members of the Ig superfamily, 
like CD28 and ICOS (inducible co­stimulator), 
and members of the TNF receptor (TNFR) 
superfamily  (TNFRSF),  like  CD27,  OX40 
(CD134), and 4­1BB (CD137), can greatly im­
pact the generation of memory CD4 and CD8 
T cells, primarily by supporting this clonal ex­
pansion of naive T cells and the accumulation 
of effector populations (Croft, 2003, 2009; 
Watts, 2005).
Once formed, memory T cells, as a popula­
tion, need to persist for a long time in the 
absence of antigen and respond rapidly upon 
antigen reexposure. Common  chain cytokines 
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Memory T helper cells (Th cells) play an important role in host defense against pathogens 
but also contribute to the pathogenesis of inflammatory disorders. We found that a  
soluble decoy lymphotoxin  receptor (LT-R)–Fc, which can block tumor necrosis factor 
(TNF)–related ligands LIGHT (TNFSF14) and LT- binding to the herpesvirus entry mediator 
(HVEM) and the LT-R, inhibited the accumulation of memory Th2 cells after antigen 
encounter and correspondingly reduced inflammatory responses in vivo. Showing that this 
was a function of the receptor for LIGHT, antigen-specific memory CD4 T cells deficient in 
HVEM were also unable to persist, despite having a normal immediate response to recall 
antigen. HVEM/ memory Th2 cells displayed reduced activity of PKB (protein kinase B; 
Akt), and constitutively active Akt rescued their survival and restored strong inflammation 
after antigen rechallenge. This was not restricted to Th2 memory cells as HVEM-deficient 
Th1 memory cells were also impaired in surviving after encounter with recall antigen. 
Furthermore, the absence of LIGHT on T cells recapitulated the defect seen with the  
absence of HVEM, suggesting that activated T cells communicate through LIGHT–HVEM 
interactions. Collectively, our results demonstrate a critical role of HVEM signals in the 
persistence of large pools of memory CD4 T cells.
© 2011 Soroosh et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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reencounter is not known. In this study, we performed a sys­
tematic analysis to identify the precise function of these mol­
ecules in recall responses of CD4 T cells. We mainly focused 
on Th2 cells as prior data have shown that these are highly 
dependent on molecules like OX40 and ICOS for their reac­
tivation (Gonzalo et al., 2001; Salek­Ardakani et al., 2003). 
In contrast to the function of these latter molecules that sup­
port expansion of memory T cells after antigen encounter, 
the presence or absence of HVEM on Th cells had no effect 
on  their  proliferation  and  immediate  accumulation  and 
function during recall responses. However, blocking of the 
HVEM–LIGHT interactions or the absence of HVEM on   
T cells severely reduced the persistence of antigen­reactive 
memory T cell pools after their secondary expansion. Th1 
memory cells were similarly impaired when HVEM could 
not be expressed. This was found to correlate with reduced 
activity of PKB (protein kinase B; Akt) and an inability to 
maintain expression of Bcl­2. Adoptive transfer experiments 
also revealed the importance of LIGHT–HVEM interactions 
between neighboring T cells in regulating the size of persist­
ing T cell memory populations. Thus, HVEM and its partner 
LIGHT play a pivotal role in the persistence of memory Th 
cells after antigen reactivation, which provides novel strate­
gies for modulating adaptive immunity during inflammatory/
allergic reactions.
RESULTS
Administration of LT-R fusion protein suppresses  
the persistence of memory Th2 cells
LIGHT binds HVEM and LT­R, and LT­ additionally 
binds  LT­R,  suggesting  possible  common  activities  of 
these molecules. Their function in regulating the response 
of memory T cells is unknown, and so we set up a model to 
specifically focus on already primed T cell populations to 
determine whether LIGHT, HVEM, or LT­ might con­
trol their activity. OVA­specific Th2 cells were generated 
from naive CD4+ TCR transgenic cells in vitro, rested, and 
then transferred into CD45.2+ congenic mice. A feature of 
primed/memory T cells is their ability to respond to soluble 
antigen in the absence of adjuvant. We therefore challenged 
the  recipient  mice  with  soluble  OVA  given  intranasally   
(i.n.) over 3 d (Fig. 1 A). To test the effects of blocking the 
interactions of LIGHT or LT­ on these Th2 popula­
tions,  LT­R  fusion  protein  (LT­R–Fc)  or  control   
human IgG was given at the time of i.n. OVA challenge. 
Interestingly, the accumulation of donor Th2 cells was sim­
ilar between LT­R–Fc­ and control IgG–treated groups 
immediately after the OVA challenges, and this was regard­
less of whether the cells were analyzed in the lung or drain­
ing LNs (Fig. S1 A). This result implied that none of these 
pathways regulated the immediate reactivity of Th2 cells to 
recall antigen.
To determine whether the interactions might be required 
for later responses, groups of mice were challenged with i.n. 
OVA and then were kept for another 4 wk without further 
antigen challenge but with LT­R–Fc given once a week 
such as IL­7 and IL­15 have been shown to support the 
maintenance of memory T cells after antigen is no longer 
available (Lenz et al., 2004; Purton et al., 2007). However, 
the factors regulating the expansion and persistence of mem­
ory cells upon secondary encounter with antigen are less well 
studied. After recall antigen stimulation, the memory T cell 
pool also expands to a great size, and again a proportion of 
these secondary effector T cells need to survive long term to 
maintain future memory. The requirement for reactivation 
and homeostasis of memory CD4 T cells has also been 
thought to require co­stimulatory signals, but the use and de­
pendence on such molecules might be more restricted than in 
the primary response. In this regard, at least one study has 
suggested that memory CD4 T cell recall responses were less 
dependent on co­stimulation by B7 and CD40 compared 
with their naive counterparts (London et al., 2000). How­
ever,  rather  than  becoming  co­stimulation  independent, 
memory CD4 T cells may shift to being more reliant on in­
ducible co­stimulatory molecules like ICOS and OX40 that 
are up­regulated on these cells upon reactivation (Gonzalo   
et al., 2001; Salek­Ardakani et al., 2003; Mahajan et al., 2007). 
Moreover, other members of the TNFRSF such as CD27 
and 4­1BB can also determine the extent of secondary ex­
pansion of memory T cells, although in these cases, it appears 
mostly through imprinting future responsiveness during the 
initial priming of naive T cells (Bertram et al., 2004; Hendriks   
et al., 2005).
The TNF family members LIGHT (TNFSF14; homolo­
gous to lymphotoxins, exhibits inducible expression, com­
petes with HSV glycoprotein D for herpesvirus entry mediator 
[HVEM], and a receptor expressed by T lymphocytes) and 
membrane lymphotoxin (LT­) have also been shown to 
promote initial T cell priming in several different models 
(Harrop et al., 1998; Mauri et al., 1998; Tamada et al., 2000, 
2002; Scheu et al., 2002; Summers­DeLuca et al., 2007) either 
through HVEM (TNFRSF14) or lymphotoxin  receptor 
(LT­R). Whereas LT­R is largely on APCs such as DCs 
and on stromal cells and might regulate the function of these 
cells, thus only indirectly affecting T cell priming, HVEM is 
expressed on most T cells (Ware, 2009). Ligation of HVEM 
by LIGHT can provide signals that also impact activation, 
differentiation, or survival of naive CD4 and CD8 T cells 
(Harrop et al., 1998; Mauri et al., 1998; Tamada et al., 2000; 
Scheu et al., 2002; Xu et al., 2007), possibly through target­
ing the induction of NF­B and AP­1 (Marsters et al., 1997; 
Harrop et al., 1998). In contrast, HVEM can also bind the 
inhibitory molecules BTLA (B and T lymphocyte attenuator) 
or CD160, and these molecules on T cells can recruit the   
tyrosine phosphatases SHP­1 and SHP­2, which subsequently 
attenuate TCR signaling (Watanabe et al., 2003; Sedy et al., 
2005; Cai and Freeman, 2009). Therefore, HVEM might 
display a dual functional activity during primary responses 
depending on ligand availability and might positively or neg­
atively impact memory T cell generation.
Whether LIGHT or HVEM controls the secondary re­
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Because LT­R–Fc prevents LIGHT–LT­R, LIGHT– 
HVEM, and LT­–LT­R interactions (Browning, 2008), 
we wanted to address which pathway was the primary me­
diator regulating the persistence of the memory cells. To 
address  this  question,  in  vitro  generated  Th2  cells  were 
adoptively transferred into LT­R/ mice, and LT­R–Fc 
or control IgG was administrated as in Fig. 1 (B–D). In 
this system, the LT­–LT­R pathway is disrupted, but 
the LIGHT–HVEM pathway is intact, as T cells do not 
express LT­R (Force et al., 1995; Murphy et al., 1998) and 
the host also could not provide LT­R. A higher number 
of total donor T cells was found in the lungs and airways of 
these mice because they do not possess LNs (Fütterer et al., 
1998), resulting in greater trafficking to this organ. However, 
similar to a WT host (Fig. 1 B), the percentage and absolute 
number of memory Th2 cells were significantly reduced in 
LT­R/ hosts treated with LT­R–Fc (Fig. 1 E). This sug­
gested that LIGHT–HVEM interactions have a fundamental 
during this time (Fig. 1 A). These mice were then challenged 
again  with  i.n.  OVA  to  induce  a  further  recall  response. 
Strikingly, the percentage and absolute number of persisting 
memory T cells were substantially reduced in mice treated 
with LT­R–Fc, regardless of whether the cells were in the 
lung, the airways, or the draining mediastinal LNs (MLNs; 
Fig. 1 B). Along with the reduced numbers of memory   
T cells, the inflammatory response in the lung as assessed by 
histology was markedly inhibited in mice receiving LT­R–Fc, 
and airway eosinophilia and Th2 cytokines were similarly   
reduced (Fig. 1, C and D). However, LT­R–Fc treatment 
did not alter the ability of the remaining donor T cells to 
produce cytokines as intracellular staining (ICS) for IL­5 and 
IL­13 showed similar levels to those of T cells from control 
mice  (Fig.  S1  B).  These  data  demonstrate  that  blocking 
LIGHT or LT­ inhibited the persistence of memory Th2 
cells as a population but did not alter the effector function of 
individual cells.
Figure 1.  LT-R fusion protein suppresses the accumulation of memory Th2 cells. (A) Experimental protocol. OVA-specific Th2 cells were gen-
erated in vitro from CD45.1+ OT-II mice as described in Material and methods. Rested Th2 cells (>99% CD4+V2+V5+) were transferred into naive WT 
or LT-R/ CD45.2+ congenic mice. Recipients were challenged with soluble OVA i.n. on a consecutive 3 d. 4 wk later, all mice were rechallenged i.n. 
with OVA on a consecutive 3 d. Groups of mice were treated with either human IgG or 100 µg LT-R–Fc as indicated. Samples were collected 24 h 
after the last OVA challenge. (B) The percentage (top) and absolute numbers (bottom) of donor (CD45.1+V2+) memory Th2 cells 24 h after the second 
recall response in BAL, lung, and MLNs of WT mice. Results are the mean ± SD from six to eight mice. (C) Representative H&E-stained lungs sections 
from WT mice treated with control (Cont) IgG or LT-R–Fc. Bar, 100 µm. (D) Numbers of BAL eosinophils and levels of BAL cytokines (IL-4, IL-5, and 
IL-13) from WT mice. (E) The percentage (left) and absolute numbers (right) of donor Th2 memory cells 24 h after the second recall response in BAL 
and lungs of LT-R/ mice. (D and E) Mean values ± SD from four to six mice per group and representative of two independent experiments are 
shown. *, P < 0.01; **, P < 0.001.800 Role of HVEM in persistence of memory T cells | Soroosh et al.
role in controlling the persistence of Th2 memory cells after 
recall antigen stimulation.
Nonredundant role for HVEM signals in T cells  
in the persistence of memory Th2 populations
To investigate whether HVEM needed to be expressed on the 
responding T cells, OVA­specific Th2 cells were generated 
from naive CD4+ T cells isolated from WT or HVEM/ 
OT­II mice (Fig. S2). These cells were then transferred into 
CD45.1+ congenic WT recipient mice, followed by soluble 
OVA recall challenges at days 1–3 and 47–49 (Fig. 2 A). Similar 
to mice treated with LT­R–Fc, the percentage and absolute 
number of donor HVEM/ memory Th2 cells were severely 
reduced in the airways, lungs, and MLNs of recipient mice   
after the second round of antigen challenges (Fig. 2 B). Again, 
showing this was physiologically relevant, analysis of the ac­
companying inflammatory response showed a profound reduc­
tion of cellular infiltrates and eosinophils in the lung compared 
with mice receiving WT T cells, and levels of Th2 cytokines in 
the airways were markedly lower (Fig. 2, C and D). To show 
this was not simply a function of the TCR transgenic system, 
HVEM/ mice primed with OVA/alum and challenged with 
recall antigen also revealed defective endogenous memory Th2 
responses (Fig. S3). Altogether, these results demonstrate that 
HVEM expressed on the CD4 T cell is required for the long­
term accumulation of high frequencies of memory T cells that 
can mediate allergic inflammatory responses.
HVEM signals are dispensable for the expansion  
and function of Th2 cells but determine the survival  
of effector cells that transition into memory populations
The severe reduction of the memory Th2 population in the 
absence of HVEM raised the question of whether HVEM also 
controlled initial expansion of Th2 cells to recall antigen. Our 
initial data with LT­R–Fc suggested that this was not the   
case (Fig. S1 A). To address this more carefully, naive WT or 
HVEM/  OVA­specific  Th2  cells  were  transferred  into 
CD45.1+ congenic WT mice as in Fig. 2, and their response 
was tracked immediately after the recipients were exposed to 
i.n. antigen (Fig. 3 A). We have previously shown that in this 
scenario, effector T cells expand in number in the draining 
LNs of the lung and then migrate to the lung to induce inflam­
mation (Salek­Ardakani et al., 2003). In contrast to our previous 
results assessing the long­term response (Fig. 2), a modest in­
crease in accumulation of HVEM/ Th2 cells was found in 
the airways, lungs, and MLNs 1 d after the last antigenic chal­
lenge, without any obvious defect (Fig. 3 B). In parallel, recipi­
ents  of  HVEM/  Th2  cells  exhibited  a  relatively  normal 
airway inflammatory response, with similar numbers of eosin­
ophils and similar levels of Th2 cytokines (Fig. S4 A). Further 
confirming that HVEM was not essential for effector function, 
direct analysis of the donor T cells revealed little production of 
IFN­ and IL­17 and normal production of IL­2 and Th2 cyto­
kines during the initial phase of antigen encounter (Fig. S4 B). 
Flow analyses also did not reveal significant differences in the 
expression of effector/differentiation markers such as CD27, 
Figure 2.  T cell–expressed HVEM is required for accumulation of 
large populations of memory Th2 cells. (A) OVA-specific Th2 cells 
were generated in vitro from CD45.2+ WT or HVEM/ OT-II mice. After 
resting, Th2 cells (>99% CD4+V2+V5+) were injected i.v. into naive WT 
CD45.1+ congenic mice. Recipient mice were subsequently challenged 
with soluble OVA i.n. on a consecutive 3 d. 6 wk later, all mice were 
rechallenged a second time with i.n. OVA on a consecutive 3 d. Samples 
were collected 24 h after the last OVA challenge. (B) The percentage and 
absolute numbers of donor memory Th2 cells in BAL, lungs, and MLNs. 
ND, not detected. (C) Representative H&E-stained lungs sections from 
the recipients of WT or HVEM/ Th2 cells. Bar, 100 µm. (D) Numbers of 
eosinophils and levels of Th2 cytokines (IL-4, IL-5, and IL-13) in BAL  
of recipients of WT and HVEM/ Th2 cells. (B and D) Results are the 
mean ± SD from six to eight mice per group and representative of two 
independent experiments. **, P < 0.001.JEM VOL. 208, April 11, 2011 
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HVEM signals in T cells prolong Akt activity during recall 
responses and support T cell survival
Previously, we showed that in the absence of another TNFRSF 
molecule, OX40, antigen­activated CD4 T cells were short­
lived because the activity of PKB (also known as Akt) was not 
maintained (Song et al., 2004). HVEM recruits the same intra­
cellular TRAF (TNFR­associated factor) adaptor proteins as 
OX40,  suggesting  possible  similarities  in  signaling.  To  see 
whether the absence of HVEM could also affect the activity of 
Akt, we initially stimulated naive WT and HVEM/ OT­II 
T cells in vitro with antigen under Th2 conditions, and the 
phosphorylation of Akt was analyzed using ICS. Maximum 
Akt phosphorylation in recently activated naive T cells is ob­
served by day 2 and can be maintained up to day 4 (Song et al., 
2004). Over this time, WT and HVEM/ T cells had com­
parable levels of phosphorylated Akt (Fig. 4 A). To determine 
whether HVEM then regulates Akt activation during recall re­
sponses, Th2 cells generated from WT and HVEM/ OT­II 
CD4 T cells were rested in fresh media and then restimulated 
with peptide­pulsed APCs. T cells were separated from APCs, 
and Akt phosphorylation was analyzed. Although initial phos­
phorylation  was  similar  over  1–2  h,  HVEM/  T  cells 
were deficient in expressing the phosphorylated form of Akt   
at later times (Fig. 4 B). Thus, HVEM directly or indirectly 
CD44, CD62L, CD127, and CXCR5 between WT and 
HVEM/ donor cells (Fig. S4 C), suggesting that defective 
long­term survival was not linked to HVEM controlling the 
early ratio of central/effector memory subsets formed.
To show that HVEM signals were active at the peak or 
after this initial effector response, WT Th2 cells were trans­
ferred into congenic hosts, and LT­R–Fc treatment was 
started 2 d after the last i.n. OVA challenge (i.e., day 5 after 
Th2 transfer; Fig. 3 C). The percentage and absolute number 
of persisting memory T cells after a further recall response were 
again significantly reduced in the mice treated with LT­R–Fc, 
regardless of whether the cells were examined in the lung, 
the airways, or the draining LNs (Fig. 3 D). Additionally, re­
cipients of HVEM/ Th2 cells were challenged with anti­
gen as before (Figs. 2 A and 3 A), and then the subsequent 
memory T cell population was analyzed after 40 d but with­
out another recall challenge (Fig. 3 E). WT Th2 cells sur­
vived  over  this  time  period  and  retained  their  cytokine 
profiles (Fig. S5), but this resting memory population did not 
develop efficiently when HVEM was absent (Fig. 3 E). 
Therefore, late HVEM–LIGHT interactions at or after the 
peak expansion phase of the recall response determine the 
number of T cells that survive during the transition from 
memory effector back to resting memory cell.
Figure 3.  HVEM is not required for the expansion of Th2 cells to recall antigen but supports the persistence of memory T cell populations.  
(A) Protocol for B. Th2 cells were generated in vitro from CD45.2+ WT or HVEM/ OT-II mice as in Fig. 2. Rested Th2 cells were transferred i.v. into congenic 
CD45.1+ WT mice, which were challenged with soluble OVA i.n. on a consecutive 3 d. (B) The percentage and absolute numbers of donor Th2 memory cells in 
BAL, lungs, and MLNs on day 4, 24 h after the last OVA challenge. (C) Protocol for D. OVA-specific Th2 cells were generated in vitro from CD45.1+ OT-II mice 
and transferred into naive WT CD45.2+ congenic mice as in Fig. 1. Recipients were challenged with soluble OVA i.n. on a consecutive 3 d. 4 wk later, all mice 
were rechallenged i.n. with OVA on a consecutive 3 d. Groups of mice were treated with either human IgG or 150 µg LT-R–Fc as indicated. (D) The percent-
age (top) and absolute numbers (bottom) of donor (CD45.1+V2+) memory Th2 cells 24 h after the second recall response in BAL, lung, and pooled MLNs of 
WT mice. (B and D) Results are the mean ± SD from four to five mice per group and representative of two independent experiments. (E) Recipients as in A 
were challenged with OVA for 3 d. 40 d later, the percentage (middle) and absolute numbers (bottom) of donor (CD45.2+V2+) WT and HVEM/ memory Th2 
cells were analyzed in spleen and MLNs. Results are the mean ± SD from six to eight mice. Cont, control; ND, not detected. *, P < 0.01; **, P < 0.001.802 Role of HVEM in persistence of memory T cells | Soroosh et al.
(myristoylated) 
Akt.  WT  or 
HVEM/ OT­
II  CD4  T  cells 
were transduced 
with  active  Akt 
or empty vector in the primary Th2 cultures (Fig. S7). Equal 
numbers of GFP­positive T cells were adoptively transferred 
into CD45.1+ congenic WT mice that were subsequently chal­
lenged with soluble OVA i.n. as in Fig. 3 A. 6 wk after the initial 
antigen challenge, the donor T cells were evaluated based on 
expression of the CD45.2 congenic marker and GFP (Fig. 5 A). 
HVEM/ T cells transduced with the control vector did not 
survive as before (Fig. 5, A and B). However, ectopic expres­
sion of active Akt completely reversed this defect, and a similar 
frequency of persisting memory T cells was found in these mice 
compared with mice that received WT T cells expressing con­
trol vector or myr­Akt (Fig. 5, A and B). To show that this 
effect was physiologically relevant, inflammation was analyzed 
after mice were further rechallenged with antigen. Severe lung 
cellular infiltration and airway eosinophilia were found in re­
cipients of HVEM/ Th2 cells expressing myr­Akt, similar to 
that observed in recipients of WT Th2 cells (Fig. 5, C and D). 
Therefore, sustained Akt activation restores the in vivo inflam­
matory response driven by memory Th2 populations by regu­
lating T cell longevity.
Blocking HVEM–LIGHT interactions between CD4 T cells 
inhibits their survival
Next, to address whether HVEM was also required for the 
maintenance of memory Th1 populations, OVA­specific Th1 
regulates Akt activity in Th2 cells undergoing a recall response 
to antigen.
To evaluate whether HVEM also prolonged Akt activity   
in vivo, rested Th2 cells generated from WT and HVEM/ 
OT­II mice were adoptively transferred into congenic WT 
mice that were subsequently challenged with i.n. OVA over 3 d, 
as in Fig. 3 A. 2 d after the last OVA challenge (i.e., 5 d after 
transfer), Akt phosphorylation was analyzed by ICS in donor 
Th2 cells recovered from MLNs of the recipient mice. Corre­
lating with the in vitro results, we found reduced expression of 
phosphorylated Akt in HVEM/ T cells (Fig. 4 C). AKT phos­
phorylation was not detected 7 d after challenge, indicating that 
its activation is prolonged in vivo but still transient (Fig. S6 A). 
Activated Akt can support T cell survival through induction of 
antiapoptotic molecules (Stahl et al., 2002; Song et al., 2004), so 
we assessed the expression of Bcl­2, and T cell apoptosis was also 
analyzed in donor Th2 cells recovered from the MLNs of recip­
ient mice at different time points after antigenic challenge. 
Paralleling reduced Akt phosphorylation, the absence of HVEM 
on T cells resulted in lower levels of Bcl­2 and enhanced T cell 
apoptosis during the later phase of the recall response at and after 
the peak of effector expansion (days 5–7; Fig. 4 C and Fig. S6 B).
Sustained Akt activity reverses defective survival  
of HVEM-deficient T cells and restores their ability  
to promote inflammation
Altogether, these observations implied that sustained Akt activ­
ity, brought about by HVEM signaling at a relatively late time 
in Th2 cells responding to recall antigen, was required to main­
tain large populations of memory cells. To test this hypothesis, 
we used a bicistronic GFP retroviral vector expressing active 
Figure 4.  HVEM signals sustain phosphoryla-
tion of AKT in Th2 cells during secondary re-
sponses and support T cell survival. (A) Naive 
CD4 T cells from WT or HVEM/ OT-II mice were 
cultured with OVA peptide–loaded APCs under Th2 
conditions. 2 (top) and 4 d (bottom) later, primed 
Th2 cells were stained for surface CD4 and intra-
cellular phosphorylated Ser-473 Akt (pAkt; solid 
line) or isotype control (closed histogram). As con-
trols for pAkt staining specificity, separate groups 
of Th2 cells were treated with 10 µM LY294002 (a 
PI3 kinase inhibitor) for the last 2 h of culture and 
then stained (dashed line). (B) OVA-specific Th2 
cells were generated as in A. After 3 d, live cells 
were rested in complete media without further 
stimulation for an additional 5 d and then subse-
quently restimulated with OVA-pulsed APCs. At 
different times, CD4+ T cells were isolated, and 
pAkt (Ser-473), total Akt, and -actin in lysates 
were analyzed by Western blotting. The amount of 
phosphorylated Akt was determined by densitom-
etry. (C) OVA-specific Th2 cells were generated as 
in A. After resting, Th2 cells were transferred into 
congenic CD45.1+ WT mice, which were subse-
quently challenged with soluble OVA i.n. on a 
consecutive 3 d. MLNs were collected 48 h after 
the last OVA challenge (5 d after transfer) and 
stained for surface CD45.2, V2, and intracellular 
pAkt, Bcl-2, or annexin V (open histograms). 
Closed histograms show isotype control staining. 
Results are representative of at least two indepen-
dent experiments. MFI, mean fluorescent intensity.JEM VOL. 208, April 11, 2011 
Article
803
whether LT­R–Fc treatment affected T cell survival, naive 
OT­II T cells were stimulated with anti­CD3 in the absence 
of APCs for 3 d and then rested in fresh media for an addi­
tional 7 d. LT­R–Fc was added during the initial 3 d, the 
last 7 d, or during the whole 10 d of culture, and T cell via­
bility was monitored at the end. Blocking LIGHT–HVEM 
interaction during the early phase of T cell stimulation had 
little effect, but blocking later significantly diminished long­
term survival of CD4 T cells (Fig. 6 C). The addition of 
LT­R–Fc for the entire 10 d of culture had the most sup­
pressive effect on T cell survival. Lastly, to evaluate whether 
this correlated with Akt activity, the T cells from these cul­
tures were harvested at days 2 and 5, and phosphorylation   
of Akt assessed. At day 2, no difference was detected, but   
T cells cultured with LT­R–Fc did not sustain the phos­
phorylation of Akt at day 5 (Fig. 6 D). Thus, although this 
was an artificial in vitro system, the results suggested that 
LIGHT–HVEM interactions between T cells might be func­
tionally relevant to long­term survival in vivo through main­
taining Akt activity.
LIGHT–HVEM interactions between CD4 T cells support 
their long-term survival in vivo
To address whether LIGHT–HVEM signaling between T cells 
can impact T cell survival in vivo, we first examined the   
expression of HVEM and LIGHT on T cells. Naive OT­II 
CD4 T cells were adoptively transferred into congenic WT 
mice  followed  by  immunization  with  OVA.  HVEM  was 
cells were generated from naive CD4+ T cells isolated from 
WT or HVEM/ OT­II mice. These cells were again trans­
ferred into CD45.1+ congenic WT recipient mice, followed 
by soluble OVA recall challenges as in Fig. 2 (Fig. 6 A). Similar 
to HVEM/ Th2 cells (Fig. 2), the percentage and absolute 
number of donor HVEM/ memory Th1 cells were severely 
reduced in the airways, lungs, and MLNs of recipient mice 
(Fig. 6 B), showing that the requirement for HVEM was not 
restricted to the Th2 phenotype.
Several sources of LIGHT have been described, includ­
ing immature DCs, monocytes, B cells, and activated T cells 
(Mauri  et  al.,  1998;  Zhai  et  al.,  1998;  Yu  et  al.,  1999; 
Tamada et al., 2000; Duhen et al., 2004). We reasoned that 
T cells might provide LIGHT to ligate HVEM on neigh­
boring T cells. To initially test whether this was possible, 
naive CD4+ T cells (CD25, CD44lo, CD62Lhi) were puri­
fied from OT­II mice and stimulated in vitro with immobi­
lized anti­CD3 in the absence of APCs. To block LIGHT– 
HVEM interaction, LT­R–Fc was added during T cell 
activation. In this APC­free system, LT­R–Fc only targets 
LIGHT–HVEM because LT­ on T cells does not have a 
receptor to engage. 3 d after stimulation, CD4 T cells pro­
liferated equally, regardless of treatment with LT­R–Fc or 
IgG, indicating that LIGHT did not contribute to the pri­
mary expansion of T cells (Fig. S8 A). However, when al­
ready primed T cells were restimulated with immobilized 
anti­CD3, those cells cultured with LT­R–Fc showed reduced 
proliferation during recall response (Fig. S8 B). To address 
Figure 5.  Active Akt reverses defective survival of HVEM/ Th2 memory cells. Naive WT or HVEM/ OT-II cells were stimulated under Th2 con-
ditions, transduced with retroviral vectors expressing either GFP alone (Mig) or GFP with myristoylated Akt (Mig-myr-Akt), and then equivalent numbers 
of GFP+ cells were transferred into groups of 8–10 naive congenic CD45.1+ WT mice. Recipient mice were challenged with soluble OVA i.n. on a consecu-
tive 3 d. 6 wk later, some mice were analyzed (memory), and some were rechallenged with OVA i.n. on a consecutive 3 d (recall memory). (A and B) The 
percentage (A) and absolute numbers (B) of donor (V2+CD45.2+GFP+) memory Th2 cells 6 wk after the primary OVA challenges (memory) in lung and 
MLNs. Results are the mean ± SD from four to six individual mice, except for the MLNs which are pooled. ND, not detected. (C) Representative H&E-
stained lungs sections from the recipient mice after the recall memory challenge. Bar, 100 µm. (D) Mean numbers of BAL eosinophils ± SD from four to six 
recipients after the recall memory challenge. Results are representative of two experiments.804 Role of HVEM in persistence of memory T cells | Soroosh et al.
(Fig. 7 A). Thus, LIGHT can be available on T cells to partner 
with HVEM.
To address whether LIGHT expressed on T cells is func­
tional as a co­stimulatory ligand regulating the development 
of memory populations, WT or LIGHT/ OT­II T cells 
highly expressed on naive T cells, down­regulated 3 d after 
antigen  stimulation,  and  then  up­regulated  by  day  10  d. 
LIGHT was not expressed on naive CD4 T cells but was in­
duced by day 3 after antigen stimulation, and interestingly, 
expression was maintained up to day 10 after immunization 
Figure 6.  Blocking HVEM–LIGHT interac-
tions between CD4 T cells suppresses their 
survival. (A) OVA-specific Th1 cells were gener-
ated in vitro from CD45.2+ WT or HVEM/ OT-II 
mice and transferred into naive WT CD45.1+ con-
genic mice. Recipient mice were subsequently 
challenged with soluble OVA i.n. on a consecutive 
3 d. 3 wk later, all mice were rechallenged a sec-
ond time with i.n. OVA on a consecutive 3 d. 
Samples were collected 24 h after the last OVA 
challenge. (B) The percentage and absolute num-
bers of donor memory Th1 cells in BAL, lungs, and 
pooled MLNs. Results are the mean ± SD from 
four to five mice per group and representative of 
two independent experiments. (C) Naive OT-II 
CD4+ T cells were stimulated with plate-bound 
anti-CD3 in the absence of APCs over 3 d. After 
being washed with PBS, cells were resuspended in 
complete fresh medium and cultured an addi-
tional 7 d. LT-R–Fc or control (Cont) Ig was 
added for 3 d starting at the beginning of the 
culture period or during the last 7 d. On day 10, 
the percentage of T survival was calculated. Data 
are the mean (±SD) of triplicate cultures, and 
similar results were obtained in at least two inde-
pendent experiments. (D) Purified naive OT-II CD4+ T cells were stimulated as in C in the presence of LT-R–Fc or control Ig. After 2 or 5 d, T cell lysates 
were analyzed for pAkt (Ser-473), total Akt, and -actin. Densitometry was performed with 1 as a reference of the highest level of pAkt normalized to 
actin expression.
Figure 7.  T cell–expressed LIGHT binding to HVEM supports the generation of memory T cell pools. (A) Purified naive CD45.2+ WT, LIGHT/,  
or HVEM/ OT-II T cells were adoptively transferred into congenic WT CD45.1+ mice. Before (day 0) and after immunization with OVA (day 3 and 10),  
the expression of HVEM and LIGHT (open histograms) on donor T cells was examined as described in Materials and methods (closed histograms  
represent LIGHT and HVEM staining of LIGHT/ and HVEM/ OT-II T cells, respectively). (B) Purified naive WT or LIGHT/ OT-II T cells were adoptively 
transferred into congenic WT CD45.1+ mice. (C) Purified naive WT or HVEM/ OT-II T cells were adoptively transferred into congenic WT CD45.1+ mice.  
(B and C) Recipients were immunized with OVA peptide, and 45 d later, numbers of donor (CD45.2+V2+) T cells were determined in spleen and peripheral 
LNs. (D) Equal numbers of CD45.2+ WT or LIGHT/ OT-II T cells were cotransferred along with CD45.1+ WT OT-II CD4 T cells into congenic WT CD45.1+ 
mice. (E) Equal numbers of CD45.2+ WT or HVEM/ OT-II T cells were cotransferred along with CD45.1+ WT OT-II CD4 T cells into congenic WT CD45.1+ 
mice. (D and E) After immunization with OVA, numbers of donor CD45.2+ cells were calculated 45 d later. (B–E) Results are the mean ± SD from four  
individual mice per group and representative of two independent experiments. ND, not detected. **, P < 0.001.JEM VOL. 208, April 11, 2011 
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showing  that  inflammation  driven  by  primed  Th2  cells   
as well as Th1 cells can be dampened by administration of 
LT­R–Fc during antigen recall responses. Studies using 
LT­R–deficient mice or in vivo treatment with LT­R–Fc 
have shown that LT­R signaling can control DC homeo­
stasis  and  function  (Gommerman  and  Browning,  2003; 
Summers­DeLuca et al., 2007), suggesting that LT­R sig­
nals on APCs could indirectly regulate the recall response of 
memory T cells. However, we now show an APC­independent 
mechanism to control inflammation via targeting LIGHT–
HVEM interactions between memory T cells responding 
after recall antigen stimulation.
The requirement for co­stimulatory signals for reactiva­
tion of antigen­experienced CD4 T cells was initially debated 
more than a decade ago. We and others suggested that these   
T cells were more reactive to antigen and TCR signals and 
less dependent on signals from APC, suggesting a reduced   
requirement  for  co­stimulation  compared  with  their  naive 
counterparts (Croft et al., 1994; Viola and Lanzavecchia, 1996; 
London et al., 2000). However, with more defined assays and 
the emergence of newer co­stimulatory interactions, this opin­
ion has changed, and several molecules including CD28/B7, 
OX40/OX40L, and ICOS/ICOSL have been shown to con­
tribute to memory CD4 T cell reactivity in various situations 
(Rogers et al., 2000; Gonzalo et al., 2001; Salek­Ardakani 
et al., 2003; Mahajan et al., 2007). Our data now add HVEM 
and LIGHT to this growing list of molecules essential for 
some aspect of memory T cell response. In contrast to 
these  aforementioned  interactions  that  primarily  determine 
the extent of secondary expansion and reactivity of memory   
T  cells  after  antigen  reencounter,  HVEM–LIGHT  signals   
allow a high frequency pool of T cells to persist after the effec­
tor phase of the recall response but with little/no impact on 
the immediate expansion and functional activity elicited by 
the recall antigen (Fig. 8).
Both HVEM and LIGHT have been reported to function 
as signaling molecules on T cells. Soluble LIGHT binding 
to HVEM or endogenous HVEM–LIGHT interactions can 
have a potent co­stimulatory action in initial T cell priming 
and early expansion of effector T cells in some situations 
(Harrop et al., 1998; Mauri et al., 1998; Tamada et al., 2000; 
were adoptively transferred into congenic WT mice that 
were  then  immunized  with  OVA.  Although  WT  and 
LIGHT/ T cells expanded equivalently within 3 d after 
activation (Fig. S8 C), few memory T cells were found in re­
cipients of LIGHT/ T cells 45 d later, regardless of location 
analyzed (Fig. 7 B). Similar results were also found compar­
ing WT with HVEM/ T cells, which expanded normally 
(Fig. S8 D) but failed to generate large numbers of memory 
cells (Fig. 7 C). Thus, LIGHT and HVEM expression were 
required in T cells for memory cell generation. To address 
this issue further and investigate which molecule was the key 
signaling molecule in antigen­responding T cells, we per­
formed coadoptive transfer experiments. WT or LIGHT/ 
(CD45.2+) T cells were cotransferred at a 1:1 ratio with WT 
(CD45.1+) T cells into WT CD45.1+ mice. Recovery of do­
nor CD45.2+ cells was assessed 45 d after antigen immuniza­
tion. WT and LIGHT/ donor T cells generated comparable 
numbers of long­lived T cells (Fig. 7 D), contrasting with the 
results of the single transfer of LIGHT/ T cells (Fig. 7 B). 
This indicated that the WT T cells (expressing LIGHT) res­
cued the survival defect of LIGHT/ T cells, implying that 
HVEM was the signaling partner. In contrast, when WT and 
HVEM/  T  cells  were  cotransferred,  few  memory  cells 
were generated from the HVEM/ donors (Fig. 7 E), simi­
lar to the defect with the single transfer of HVEM/ cells 
(Fig. 7 C). Therefore, these results demonstrate that HVEM 
is the key co­stimulatory molecule that promotes survival of 
large  pools  of  memory  T  cells,  through  interacting  with 
LIGHT expressed on neighboring antigen­specific T cells.
DISCUSSION
Targeting antigen­experienced T cells may be an effective 
therapeutic strategy for treatment of ongoing or recurring 
inflammation. Previous studies have shown that LT­R–Fc 
decoy protein has potent suppressive effects in controlling 
disease in several Th1/Th17 autoimmune models (Mackay   
et al., 1998; Wu et al., 2001; Tamada et al., 2002; Gommerman 
et al., 2003), suggesting that LT­–LT­R, LIGHT–HVEM, 
or LIGHT–LT­R interactions (Browning, 2008) might be 
highly active in promoting inflammation. We now add to 
our understanding of the importance of these pathways by 
Figure 8.  Model depicting how HVEM–LIGHT interactions control recall antigen responses, acting at or after the peak phase of expansion 
of effector T cells, to provide survival signals to allow the persistence of high numbers of memory T cells.806 Role of HVEM in persistence of memory T cells | Soroosh et al.
Sedy et al., 2005; Cai and Freeman, 2009; Cheung et al., 
2009b). Therefore, the time of availability of LIGHT and 
other ligands may determine the overall signaling activity of 
HVEM. We also found some evidence of hyper­responsiveness 
in the initial response to recall antigen with increased accu­
mulation of HVEM/ Th2 cells in the airways, lungs, and 
MLNs (Fig. 3 B). However, over time, a lack of HVEM trans­
lated into the loss of memory T cells. This suggests that al­
though BTLA or CD160 might have been active initially, 
LIGHT is the primary stimulus that dictated the overall size 
of the antigen­reactive T cell population that subsequently 
resulted after the antigen cleared.
There are few studies that have addressed the signaling 
events downstream of HVEM. Cross­linking HVEM on   
human T cells was found to recruit TRAF adaptor molecules, 
leading to activation of NF­B and AP­1 (Marsters et al., 
1997; Harrop et al., 1998). Also, activation of HVEM on 
monocytes  induced  the  phosphorylation  of  phospholipase 
C1 after a rapid elevation of intracellular calcium (Heo et al., 
2007), and ligation of HVEM by LIGHT induced macro­
phage migration and smooth muscle proliferation that was 
associated with the activation of several signaling pathways, 
including mitogen­activated protein kinases, phosphoinositide 
3­kinase/Akt, and NF­B (Wei et al., 2006). In this study, 
we found both in vitro and in vivo that HVEM­deficient   
T cells did not maintain Akt activity during recall responses 
that paralleled defective expression of the antiapoptotic mol­
ecule Bcl­2 and reduced T cell survival. Determining whether 
HVEM directly recruits Akt to its intracellular tail or en­
hances TCR­driven Akt activity or only indirectly prolongs 
Akt activity by regulating the expression of other membrane 
receptors that can target this pathway requires further analy­
sis. However, defective T cell survival in the absence of HVEM 
could be fully rescued by ectopic expression of an active form 
of Akt, indicating the central role of sustaining Akt activation 
in regulating T cell longevity and the size of persisting memory 
T cell pools.
In summary, our experiments show a critical role for LIGHT– 
HVEM signals in the generation and maintenance of long­
lived memory Th cell populations after the recall response to 
soluble antigen. Because both Th2 and Th1 cells have been 
shown to play a critical role in perpetuating inflammation, 
our findings indicate that targeting the LIGHT–HVEM path­
way  may  lead  to  effective  therapeutic  strategies  in  which 
memory Th2 and Th1 cells are pathogenic.
MATERIALS AND METHODS
Mice.  6–8­wk­old  female  C57BL/6  (CD45.2+)  and  C57BL/6­SJL 
(CD45.1+) WT mice were purchased from the Jackson Laboratory. LIGHT­
deficient (LIGHT/), HVEM­deficient (HVEM/), and LT­R–deficient 
(LT­R/) mice (CD45.2+) were generated by K. Pfeffer and bred in­
house at La Jolla Institute for Allergy and Immunology and have been de­
scribed previously (Cheung et al., 2009a). OT­II TCR transgenic mice 
(CD45.2+) were a gift from W. Heath (Walter and Eliza Hall Institute of 
Medical  Research,  Melbourne,  Australia)  and  were  used  as  a  source  of 
V2+V5+ CD4 T cells responsive to the OVA 323–339 peptide (Barnden 
et al., 1998). CD45.1+ OT­II transgenic mice were generated by backcrossing 
Shaikh et al., 2001; Wang et al., 2001). For example, a recent 
study  demonstrated  that  expression  of  HVEM  on  T  cells 
controlled the size of alloreactive CD4 and CD8 T cell pools 
that formed over a 10­d period in a graft­versus­host disease 
model (Xu et al., 2007). In contrast, cross­linking LIGHT on 
T cells has also been shown to enhance T cell proliferation 
and cytokine production after triggering the TCR (Shi et al., 
2002; Wan et al., 2002). In line with these studies, we found 
that HVEM/ and LIGHT/ CD4 T cells displayed iden­
tical defects in generating long­lived memory T cells when 
responding separately in adoptive hosts. The common phe­
notype indicated that LIGHT–HVEM form a signaling path­
way but did not resolve in this setting which molecule served 
as the signaling element regulating memory T cells. How­
ever, when WT and LIGHT/ T cells were cotransferred 
and stimulated together in vivo, comparable numbers of 
long­lived  T  cells  accumulated,  which  contrasted  sharply 
with the defect when WT and HVEM/ T cells were co­
transferred. These results strongly support the conclusion that 
HVEM serves as the primary signaling element and also sug­
gest that it is T cell–derived LIGHT that is sufficient to pro­
vide the necessary HVEM signal. Our conclusions are also in 
line with prior data in vitro, which showed that blocking this 
interaction reduced T cell proliferation to anti­CD3, and 
data in vivo, in which constitutive expression of LIGHT on 
T cells resulted in several autoimmune symptoms typical of   
T cell driven responses (Shaikh et al., 2001; Wang et al., 
2001). Based on these observations and our data, we there­
fore propose a model for Th memory in which engagement 
of HVEM on these activated cells by trans interaction with 
LIGHT expressed on adjacent effector T cells provides late 
co­stimulatory signals that promote T cell survival after the 
recall immune response is established (Fig. 8). Although ex­
pression of LIGHT on APCs such as DCs and B cells also 
could provide HVEM signals in some scenarios, sustained ex­
pression of LIGHT in antigen­responsive T cells clustered in 
the niche of the T cell zone of secondary and tertiary lym­
phoid organs is likely to represent a major source of LIGHT, 
allowing direct T cell–T cell communication.
The precise function of HVEM as either a stimulatory or 
inhibitory receptor has been the subject of debate for some 
time. HVEM is ubiquitously expressed on many different 
types of cells and also can bind to multiple ligands (Cheung 
et al., 2009b). Although one study showed that blocking 
HVEM in vitro led to a reduction in T cell proliferation 
(Wang et al., 2001), another suggested that HVEM/ T cells 
were  hyper­responsive  to  anti­CD3–mediated  stimulation 
(Wang et al., 2005). In line with this potential suppressive 
action,  HVEM/  mice  were  more  susceptible  to  Con   
A–mediated T cell–dependent autoimmune hepatitis and 
myelin  oligodendrocyte  glycoprotein  peptide–induced 
experimental autoimmune encephalomyelitis (Wang et al., 
2005).  The  explanation  for  the  latter  phenotypes  is  that 
HVEM can also bind to BTLA and CD160, and these mole­
cules can induce inhibitory signals into T cells when ex­
pressed in cis or in trans in T cells (Watanabe et al., 2003; JEM VOL. 208, April 11, 2011 
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was used to visualize biotin­labeled antibodies. Human IgG was purchased 
from  Bethyl  Laboratories,  Inc.  LT­R  fused  with  the  Fc  portion  of   
human  IgG  (LT­R–Fc)  was  made  in­house  (De  Trez  et  al.,  2008). 
Anti–HVEM­PE, anti–human IgG (heavy chain), anti–IL­2, anti–IL­4, 
anti–IL­5,  anti–IL­13  (all  PE  or  allophycocyanin  conjugated),  and   
annexin V detection kit were obtained from eBioscience. Anti–phospho­
Ser (473) Akt, anti­Akt, anti– actin, isotype match control antibody, 
LY294002 (PI3 kinase inhibitor), and peroxidase­conjugated anti–rabbit­
Ig were obtained from Cell Signaling Technology. Reagents for cell fixa­
tion and permeabilization for detecting intracellular cytokines, Bcl­2, and 
phospho­Akt were obtained from BD, and staining was performed ac­
cording to the manufacturer’s instructions. For LIGHT staining, LT­ 
expression was first blocked on donor CD4 T cells with anti–LT­ (BBF6; 
a gift from J. Browning [Biogen Idec, Cambridge, MA] to the Ware labora­
tory), followed by incubation with LT­R–Fc and PE­conjugated anti–
human Ig (Summers­DeLuca et al., 2007). Cells were examined by flow 
cytometry by using the FACSCalibur (BD) and analyzed with FlowJo soft­
ware (Tree Star).
In vitro T cell stimulation and immunoblotting. Naive CD4 T cells 
were isolated from spleen and peripheral LNs of WT or HVEM/ OT­II 
mice as described previously (Song et al., 2004) and stimulated with plate­
bound anti­CD3 or OVA­pulsed APCs under Th2 or neutral conditions. 
After resting in fresh media, effector T cells were restimulated with   
OVA­pulsed APCs followed by isolation of CD4+ T cells using CD4 
MicroBeads (Miltenyi Biotec). Purified CD4+ T cells were lysed and then 
subjected to immunoblotting as described previously (Song et al., 2004). 
To block LIGHT–HVEM interactions, 10 µg/ml LT­R–Fc was added 
during CD4 T cell stimulation in the absence of APC as indicated. In some 
cases, proliferation was measured in triplicate by the incorporation of 
[3H]thymidine (1 µCi/well; ICN Pharmaceuticals) during the last 8 h of 
each culture. In vitro T cell survival was determined by Trypan blue   
exclusion, and the percent recovery was calculated based on the input 
number of cells.
Retroviral transduction. Internal ribosome entry site GFP (Mig) retrovi­
ral vectors with constitutively active (myristoylated) Akt (Mig­myr­Akt) 
were described previously (Song et al., 2004). Transduction of CD4 T cells 
was performed as described previously with some minor changes (Song 
et al., 2004). In brief, the virus was produced by chloroquine­mediated cal­
cium phosphate transfection of the Plat E packaging cell. Supernatants were 
collected after 3 d, titered by GFP expression, and used directly for transduc­
ing T cells. Naive CD4+ T cells were stimulated with plate­bound anti­CD3 
and soluble anti­CD28 under Th2 conditions as described in Adoptive trans­
fer and induction of lung inflammation. After 2 d, the supernatant was re­
placed with 500 µl of viral supernatant containing 5 g/ml polybrene. The 
cells were spun for 2 h at 32°C and then incubated at 32°C for 8 h. This 
procedure was repeated the following day. Viral supernatant was removed 
and replaced with fresh medium containing 2 ng/ml IL­4, and T cells were 
recultured. Expression of GFP was determined by flow cytometry on CD4 
T cells.
Online supplemental material. Fig. S1 shows that LT­R–Fc treatment 
does not affect accumulation or cytokine secretion of Th2 cells immediately 
after recall antigen. Fig. S2 shows the cytokine profile of Th2 cells before 
transfer into the mice. Fig. S3 shows that HVEM signals support optimal 
generation of endogenous polyclonal memory Th2 populations. Fig. S4 shows 
that HVEM is not required for the differentiation and effector function of 
Th2 cells. Fig. S5 shows the cytokine profile and phenotype of memory Th2   
cells. Fig. S6 shows the reduction of Bcl­2 expression and increased apopto­
sis of Th2 cells in the absence of HVEM signals. Fig. S7 shows the efficiency 
of retroviral transduction of Th2 cells with active Akt. Fig. S8 shows that 
LIGHT and HVEM do not affect primary expansion of CD4 T cells. Online   
supplemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20101562/DC1.
OT­II  mice  with  CD45.1+  mice.  CD45.2+  HVEM/  and  LIGHT/  
OT­II mice were generated in­house by intercrossing. All mice were back­
crossed at least 10 times. The experiments reported in this study conform to 
the principles outlined by the animal Welfare Act and the National Insti­
tutes of Health guidelines for the care and use of animals in biomedical re­
search. All experiments were performed in compliance with the regulations 
of the La Jolla Institute Animal Care committee in accordance with the 
guidelines by the Association for Assessment and Accreditation of Labora­
tory Animal Care.
Adoptive transfer and induction of lung inflammation. Naive CD4   
T cells were purified from spleen and peripheral LNs of WT or HVEM/ 
OT­II mice using a naive CD4 T cell isolation kit II (Miltenyi Biotec) and 
AutoMACS Pro cell separator (Miltenyi Biotec). In some cases, naive CD4 
T cells (CD62LhiCD44loCD25) were purified using a FACSAria II cell 
sorter (BD). To generate Th2 cells, naive CD4 T cells were stimulated either 
with 1 µg/ml plate­bound anti­CD3 and 5 µg/ml soluble anti­CD28 or 
with 1 µM OVA peptide (Abgent)–pulsed T cell–depleted splenic APCs in 
the presence of 20 ng/ml IL­4, 10 µg/ml anti–IFN­, and 10 µg/ml anti–
IL­12 for 3 d. To generate Th1 cells, naive CD4 T cells were stimulated 
with 1 µM OVA peptide–pulsed T cell–depleted splenic APCs in the pres­
ence of 2 ng/ml IL­12 and 10 µg/ml anti–IL­4 for 3 d. Highly activated 
Th2/Th1 cells were washed and rested in fresh complete media for another 
3–6 d without further stimulation. Rested Th cells (2–3 × 106; >99% 
CD4+V2+V5+) were injected i.v. into congenic naive mice. 1 d after 
transfer of cells, mice were challenged i.n. with 20–50 µg/ml soluble OVA 
protein (chicken egg OVA grade V; Sigma­Aldrich) for a consecutive 3 d. 
Some animals were sacrificed for analysis 1 d later to assess secondary recall 
responses. Some mice were kept for 45–60 d to study secondary memory 
cells and further challenged i.n. with OVA for a consecutive 3 d to evaluate 
tertiary recall responses. To block LIGHT–HVEM interactions, mice were 
injected i.p. with 100–150 µg LT­R–Fc or human IgG (Bethyl Laborato­
ries, Inc.) as an isotype control antibody on the indicated days, 24 h before 
OVA challenge.
In other experiments, congenic CD45.1 naive mice received i.v. 2.5 × 
104 purified WT, HVEM/, or LIGHT/ naive CD45.2+ OT­II CD4+  
T cells by adoptive transfer. In some cases, 2.5 × 104 CD45.1+ WT OT­II 
CD4 T cells were cotransferred with 2.5 × 104 CD45.2+ T cells. In both 
cases,  recipient  mice  were  immunized  i.v.  with  100  µg  OVA  323–339   
peptide plus 50 µg LPS (Enzo Life Sciences) 1 d after T cell transfer. At 
different  time  points,  the  percentage  and  absolute  number  of  donor 
CD45.2+ T cells and surface expression of HVEM and LIGHT on donor 
cells were determined.
Analysis of lung inflammation. Mice were killed 1 d after the last OVA 
challenge, and bronchoalveolar lavage (BAL) fluid, lungs, and lung­draining 
LNs were obtained. BAL was performed by intratracheal insertion of cathe­
ter, lavaging with 0.8–0.9 ml of 2% filtered BSA (Sigma­Aldrich). BAL dif­
ferential cell counts, FACS analysis, and ELISA for cytokines were performed 
as described previously (Salek­Ardakani et al., 2003). The right hilum was 
tied off, and right lungs were isolated and digested for cellular analysis as de­
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